Blog
RSS FeedPosted by Michael Wonder on 04 Feb 2021
Bayer receives approval for Nubeqa in China for the treatment of men with non-metastatic castration-resistant prostate cancer
3 February 2021 - The Chinese National Medical Products Administration (NMPA) has approved Nubeqa (darolutamide) for the treatment of patients with ...
Posted by Michael Wonder on 04 Feb 2021
Astellas' Xospata (gilteritinib) receives conditional approval by China's National Medical Products Administration for relapsed or refractory acute myeloid leukaemia with a FLT3 mutation
3 February 2021 - Accelerated approval follows priority review designation and inclusion in overseas new drugs urgently needed in clinical settings. ...
Posted by Michael Wonder on 04 Feb 2021
Forxiga approved in China for heart failure
4 February 2021 - Forxiga is the first SGLT2 inhibitor approved in China for heart failure with reduced ejection fraction in ...
Posted by Michael Wonder on 26 Jan 2021
Symbicort Turbuhaler approved in China as an anti-inflammatory reliever in mild asthma
26 January 2021 - Symbicort Turbuhaler becomes the first dual-combination therapy approved in China for mild, moderate and severe asthma ...
Posted by Michael Wonder on 15 Jan 2021
China National Medical Products Administration approves tislelizumab in combination with chemotherapy in first-line advanced squamous non-small cell lung cancer
13 January 2021 - BeiGene today announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products ...
Posted by Michael Wonder on 13 Jan 2021
Innovent announces NMPA acceptance of a supplemental new drug application for Tyvyt (sintilimab injection) in combination with Byvasda (bevacizumab injection) as first-line therapy in hepatocellular carcinoma
12 January 2021 - Innovent Biologics today announced that the National Medical Products Administration of China has accepted the supplemental ...
Posted by Michael Wonder on 30 Dec 2020
Zai Lab announces inclusion of Zejula (niraparib) in China’s National Reimbursement Drug List
28 December 2020 - Zai Lab today announced that Zejula has been included in the updated National Reimbursement Drug List released ...
Posted by Michael Wonder on 30 Dec 2020
BeiGene announces inclusion of three innovative oncology products in China National Reimbursement Drug List
27 December 2020 - Internally-developed anti-PD-1 antibody tislelizumab and BTK inhibitor Brukinsa (zanubrutinib) are included in the National Reimbursement Drug List ...
Posted by Michael Wonder on 30 Dec 2020
Junshi Biosciences announces inclusion of toripalimab in the China National Reimbursement Drug List
29 December 2020 - Junshi Biosciences is pleased to announce that toripalimab has been included in the updated National Reimbursement Drug ...
Posted by Michael Wonder on 09 Dec 2020
BeiGene announces the approval in China of Blincyto (blinatumomab) for injection for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
7 December 2020 - BeiGene today announced that the China NMPA has approved Blincyto (blinatumomab) for injection for the treatment of ...
Posted by Michael Wonder on 23 Nov 2020
BeiGene announces the approval of Xgeva (denosumab) in China for the prevention of skeletal-related events in patients with bone metastases from solid tumours and in patients with multiple myeloma
19 November 2020 - BeiGene today announced that the China NMPA has approved Xgeva (denosumab) for the prevention of skeletal-related events ...
Posted by Michael Wonder on 17 Nov 2020
TRACON Pharmaceuticals announces submission for approval of envafolimab (KN035) with the NMPA in China by its corporate partners Alphamab Oncology and 3D Medicine
16 November 2020 - TRACON Pharmaceuticals today announced its corporate partners, Alphamab Oncology and 3D Medicines, have submitted a new drug ...
Posted by Michael Wonder on 10 Nov 2020
EUSA Pharma and BeiGene announce acceptance of a biologics license application for Qarziba (dinutuximab beta) in Chin
9 November 2020 - EUSA Pharma and BeiGene today announced that the biologics license application for Qarziba (dinutuximab beta) was accepted ...
Posted by Michael Wonder on 06 Nov 2020
Xtandi (enzalutamide soft capsules) approved by China NMPA for the treatment of non-metastatic castration-resistant prostate cancer
6 November 2020 - Enzalutamide is now NMPA approved for both non-metastatic and metastatic castration-resistant prostate cancer. ...
Posted by Michael Wonder on 03 Nov 2020
How people in China with rare diseases afford outrageously expensive medicines?
3 November 2020 - Sky high prices are common for patients with rare diseases. ...